These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 23513884)

  • 21. Mammalian target of rapamycin as a target in hematological malignancies.
    Abdel-Karim IA; Giles FJ
    Curr Probl Cancer; 2008; 32(4):161-77. PubMed ID: 18655914
    [No Abstract]   [Full Text] [Related]  

  • 22. [Pancreatic cancer: Roche versus the European Agency of Drugs].
    Nau JY
    Rev Med Suisse; 2006 Aug; 2(76):1937. PubMed ID: 16972545
    [No Abstract]   [Full Text] [Related]  

  • 23. Targeted therapy for lung cancer.
    Petrosyan F; Daw H; Haddad A; Spiro T
    Anticancer Drugs; 2012 Nov; 23(10):1016-21. PubMed ID: 22932130
    [TBL] [Abstract][Full Text] [Related]  

  • 24. From targets to treatments: a review of molecular targets in pancreatic neuroendocrine tumors.
    Wiedenmann B; Pavel M; Kos-Kudla B
    Neuroendocrinology; 2011; 94(3):177-90. PubMed ID: 21893937
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prolonged response to temsirolimus in a pre-treated patient with metastatic renal cell carcinoma and poor performance status.
    Jafri M; Douis H; Porfiri E
    Clin Oncol (R Coll Radiol); 2008 Oct; 20(8):657-8. PubMed ID: 18644704
    [No Abstract]   [Full Text] [Related]  

  • 26. Well-differentiated pancreatic islet cell carcinoma: Is there reversibility in mTOR inhibitor resistance?
    Walter T; Scoazec JY; Couderc C; Forestier J; Roche C; Chayvialle JA; Lombard-Bohas C
    Acta Oncol; 2011 Jun; 50(5):731-2. PubMed ID: 21413853
    [No Abstract]   [Full Text] [Related]  

  • 27. Neuroendocrine tumors: nursing implications for oral targeted agents and patient management: Part II.
    Jacobs C
    Clin J Oncol Nurs; 2009 Apr; 13(2):149-53. PubMed ID: 19349261
    [No Abstract]   [Full Text] [Related]  

  • 28. [Personalized treatment in non-small cell lung cancer].
    Campos-Parra AD; Cruz-Rico G; Arrieta O
    Rev Invest Clin; 2012; 64(4):377-86. PubMed ID: 23227588
    [No Abstract]   [Full Text] [Related]  

  • 29. A case of rapid improvement of severe psoriasis during molecular-targeted therapy using an epidermal growth factor receptor tyrosine kinase inhibitor for metastatic lung adenocarcinoma.
    Oyama N; Kaneko F; Togashi A; Yamamoto T
    J Am Acad Dermatol; 2012 Jun; 66(6):e251-3. PubMed ID: 22583734
    [No Abstract]   [Full Text] [Related]  

  • 30. Glycemic control in patients with insulinoma treated with everolimus.
    Kulke MH; Bergsland EK; Yao JC
    N Engl J Med; 2009 Jan; 360(2):195-7. PubMed ID: 19129539
    [No Abstract]   [Full Text] [Related]  

  • 31. Medical treatment of neuroendocrine tumours.
    Weber HC
    Curr Opin Endocrinol Diabetes Obes; 2013 Feb; 20(1):27-31. PubMed ID: 23221494
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Emerging therapeutic targets and agents for pancreatic cancer therapy--where are we and where we have to go?
    Sebens S; Kalthoff H
    Anticancer Agents Med Chem; 2011 Jun; 11(5):408-10. PubMed ID: 21492077
    [No Abstract]   [Full Text] [Related]  

  • 33. [Future direction of medical oncology in Japan].
    Nakagawa K
    Nihon Rinsho; 2012 Nov; 70 Suppl 8():1-4. PubMed ID: 23513802
    [No Abstract]   [Full Text] [Related]  

  • 34. Hormonal manipulation in the treatment of pancreatic carcinoma.
    Greenway BA
    Br J Surg; 1988 Feb; 75(2):187. PubMed ID: 3349314
    [No Abstract]   [Full Text] [Related]  

  • 35. [Pancreatic carcinoma].
    Okamoto T; Onda S
    Nihon Rinsho; 2012 Nov; 70 Suppl 8():463-7. PubMed ID: 23513884
    [No Abstract]   [Full Text] [Related]  

  • 36. Erlotinib in pancreatic cancer patients: do we need more information from the NCIC CTG trial?
    Mandalà M; Moro C; Labianca R; Ferretti G
    J Clin Oncol; 2007 Sep; 25(27):4320-1; author reply 4321-2. PubMed ID: 17878488
    [No Abstract]   [Full Text] [Related]  

  • 37. Combining epidermal growth factor receptor inhibitors and radiation therapy in pancreatic cancer: small step or giant leap?
    Chang BW; Saif MW
    JOP; 2009 May; 10(3):231-6. PubMed ID: 19454812
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Erlotinib: success of a molecularly targeted agent for the treatment of advanced pancreatic cancer.
    Welch SA; Moore MJ
    Future Oncol; 2007 Jun; 3(3):247-54. PubMed ID: 17547518
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Perspectives in central nervous system malignancies.
    Stummer W
    IDrugs; 2006 Jun; 9(6):412-4. PubMed ID: 16752310
    [No Abstract]   [Full Text] [Related]  

  • 40. [Report from a small registry-permetrexed, tarceva and yondelis].
    Pochop L; Hejduk K
    Klin Onkol; 2013; 26(1):53-4. PubMed ID: 23607142
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.